Sep 30, 2024

Lantheus Q3 2024 Earnings Report

Reported an increase in worldwide revenue and adjusted EPS, driven by strong performance of PYLARIFY and DEFINITY, and expanded its Alzheimer's disease radiodiagnostics portfolio.

Key Takeaways

Lantheus reported a strong Q3 2024 with an 18.4% increase in worldwide revenue to $378.7 million. GAAP EPS was $1.79, while adjusted EPS was $1.70. The company is narrowing its full-year 2024 revenue and EPS guidance towards the higher end of previous estimates.

Worldwide revenue increased by 18.4% to $378.7 million compared to Q3 2023.

PYLARIFY sales increased by 20.6% to $259.8 million, driven by increasing volumes at existing accounts.

DEFINITY sales increased by 14.3% to $77.0 million, driven by market growth and competitor supply challenges.

GAAP fully diluted earnings per share decreased to $1.79, while adjusted fully diluted earnings per share increased by 15.6% to $1.70.

Total Revenue
$379M
Previous year: $320M
+18.4%
EPS
$1.7
Previous year: $1.47
+15.6%
Gross Profit
$242M
Previous year: $200M
+21.1%
Cash and Equivalents
$866M
Previous year: $614M
+41.1%
Free Cash Flow
$159M
Previous year: $102M
+56.0%
Total Assets
$2.05B
Previous year: $1.52B
+34.7%

Lantheus

Lantheus

Lantheus Revenue by Segment

Forward Guidance

The company narrows full year 2024 revenue and fully diluted earnings per share guidance towards higher end of the previously issued guidance.